• Recovery phase and preparation for Vision 2030 – Toyobo now approaches the completion of its current medium-term plan (FY3/23–FY3/26). Performance is expected to fall short of initial targets, primarily due to upfront growth investments and delays in portfolio restructuring. However, recovery has become visible from Q1–2 FY3/26, with Businesses requiring improvement (namely Textiles, Pharmaceuticals, Airbag Fabrics, Packaging Films, and Nonwoven Materials) returning to positive OP, alongside a turnaround in free cash flow. With six action plans in place to strengthen profitability and capex expected to normalize, we expect earnings and free cash flow to continue improving from FY3/26 onward, supporting Toyobo’s progression toward its Vision 2030 targets (OP margin of 8.3% and ROE of 8.0%).
21 Jan 2026
Toyobo (3101) Deep-dive review 2026: Rejuvenation through portfolio optimization and improved returns
Toyobo Co., Ltd. (3101:TKS), 0 | Toray Industries, Inc. (3402:TKS), 0 | Mitsubishi Chemical Group Corporation (4188:TKS), 0 | Kuraray Co., Ltd. (3405:TKS), 0 | Teijin Limited (3401:TKS), 0 | Unitika Ltd. (3103:TKS), 0 | Asahi Kasei Corporation (3407:TKS), 0 | Nisshinbo Holdings Inc. (3105:TKS), 0 | Shikibo Ltd. (3109:TKS), 0 | Kureha Corporation (4023:TKS), 0 | Resonac Holdings Corporation (4004:TKS), 0 | KURABO INDUSTRIES LTD. (3106:TKS), 0 | UBE Corporation (4208:TKS), 0 | Seiren Co., Ltd. (3569:TKS), 0 | DuPont de Nemours Inc (DD:NYSE), 0 | Dow, Inc. (DOW:NYS), 0 | BASF SE (BAS:ETR), 0 | 3M Company (MMM:NYS), 0 | Evonik Industries AG (EVK:ETR), 0 | Srf Limited (503806:BOM), 0
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Toyobo (3101) Deep-dive review 2026: Rejuvenation through portfolio optimization and improved returns
Toyobo Co., Ltd. (3101:TKS), 0 | Toray Industries, Inc. (3402:TKS), 0 | Mitsubishi Chemical Group Corporation (4188:TKS), 0 | Kuraray Co., Ltd. (3405:TKS), 0 | Teijin Limited (3401:TKS), 0 | Unitika Ltd. (3103:TKS), 0 | Asahi Kasei Corporation (3407:TKS), 0 | Nisshinbo Holdings Inc. (3105:TKS), 0 | Shikibo Ltd. (3109:TKS), 0 | Kureha Corporation (4023:TKS), 0 | Resonac Holdings Corporation (4004:TKS), 0 | KURABO INDUSTRIES LTD. (3106:TKS), 0 | UBE Corporation (4208:TKS), 0 | Seiren Co., Ltd. (3569:TKS), 0 | DuPont de Nemours Inc (DD:NYSE), 0 | Dow, Inc. (DOW:NYS), 0 | BASF SE (BAS:ETR), 0 | 3M Company (MMM:NYS), 0 | Evonik Industries AG (EVK:ETR), 0 | Srf Limited (503806:BOM), 0
- Published:
21 Jan 2026 - Author:
-
Pages:
43 -
• Recovery phase and preparation for Vision 2030 – Toyobo now approaches the completion of its current medium-term plan (FY3/23–FY3/26). Performance is expected to fall short of initial targets, primarily due to upfront growth investments and delays in portfolio restructuring. However, recovery has become visible from Q1–2 FY3/26, with Businesses requiring improvement (namely Textiles, Pharmaceuticals, Airbag Fabrics, Packaging Films, and Nonwoven Materials) returning to positive OP, alongside a turnaround in free cash flow. With six action plans in place to strengthen profitability and capex expected to normalize, we expect earnings and free cash flow to continue improving from FY3/26 onward, supporting Toyobo’s progression toward its Vision 2030 targets (OP margin of 8.3% and ROE of 8.0%).